Section 191: Advanced Lipid Signaling Modulators in CBS/PSP

Migration, Crosslink

📖

Section 191: Advanced Lipid Signaling Modulators in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-191-advanced-l

📖 Wiki Page

therapeutic2291 wordssynced 2026-04-02

Section 191: Advanced Lipid Signaling Modulators in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 191: Advanced Lipid Signaling Modulators in CBS/PSP</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">LPA1</td>
<td>Neurons, astrocytes</td>
</tr>
<tr>
<td class="label">LPA2</td>
<td>Immune cells</td>
</tr>
<tr>
<td class="label">LPA3</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">LPA4</td>
<td>Glia</td>
</tr>
<tr>
<td class="label">LPA5</td>
<td>Platelets</td>
</tr>
<tr>
<td class="label">LPA6</td>
<td>Neural stem cells</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AM095</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">AM152</td>
<td>LPA1/2</td>
</tr>
<tr>
<td class="label">Ki16425</td>
<td>LPA1/2/3</td>
</tr>
<tr>
<td class="label">Compound 35</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Cell Types</td>
</tr>
<tr>
<td class="label">S1PR1</td>
<td>Lymphocytes, neurons</td>
</tr>
<tr>
<td class="label">S1PR2</td>
<td>Neurons, oligodendrocytes</td>
</tr>
<tr>
<td class="label">S1PR3</td>
<td>Neurons, astrocytes</td>
</tr>
<tr>
<td class="label">S1PR4</td>
<td>Immune cells</td>
</tr>
<tr>
<td class="label">S1PR5</td>
<td>Oligodendrocytes, NK cells</td>
</tr>
<tr>

...

Section 191: Advanced Lipid Signaling Modulators in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 191: Advanced Lipid Signaling Modulators in CBS/PSP</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">LPA1</td>
<td>Neurons, astrocytes</td>
</tr>
<tr>
<td class="label">LPA2</td>
<td>Immune cells</td>
</tr>
<tr>
<td class="label">LPA3</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">LPA4</td>
<td>Glia</td>
</tr>
<tr>
<td class="label">LPA5</td>
<td>Platelets</td>
</tr>
<tr>
<td class="label">LPA6</td>
<td>Neural stem cells</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AM095</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">AM152</td>
<td>LPA1/2</td>
</tr>
<tr>
<td class="label">Ki16425</td>
<td>LPA1/2/3</td>
</tr>
<tr>
<td class="label">Compound 35</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Cell Types</td>
</tr>
<tr>
<td class="label">S1PR1</td>
<td>Lymphocytes, neurons</td>
</tr>
<tr>
<td class="label">S1PR2</td>
<td>Neurons, oligodendrocytes</td>
</tr>
<tr>
<td class="label">S1PR3</td>
<td>Neurons, astrocytes</td>
</tr>
<tr>
<td class="label">S1PR4</td>
<td>Immune cells</td>
</tr>
<tr>
<td class="label">S1PR5</td>
<td>Oligodendrocytes, NK cells</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Targets</td>
</tr>
<tr>
<td class="label">Fingolimod (Gilenya)</td>
<td>S1PR1,3,4,5</td>
</tr>
<tr>
<td class="label">Siponimod (Mayzent)</td>
<td>S1PR1,5</td>
</tr>
<tr>
<td class="label">Ozanimod (Zeposia)</td>
<td>S1PR1,5</td>
</tr>
<tr>
<td class="label">Ponesimod (Ponvory)</td>
<td>S1PR1</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">—</td>
<td>Fingolimod</td>
</tr>
<tr>
<td class="label">—</td>
<td>Fingolimod</td>
</tr>
<tr>
<td class="label">NCT06639282</td>
<td>Siponimod</td>
</tr>
<tr>
<td class="label">Day</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">1</td>
<td>0.25 mg</td>
</tr>
<tr>
<td class="label">2</td>
<td>0.25 mg</td>
</tr>
<tr>
<td class="label">3</td>
<td>0.5 mg</td>
</tr>
<tr>
<td class="label">4</td>
<td>0.75 mg</td>
</tr>
<tr>
<td class="label">5+</td>
<td>2 mg (maintenance)</td>
</tr>
<tr>
<td class="label">Oxysterol</td>
<td>Source</td>
</tr>
<tr>
<td class="label">24OHC</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">27OHC</td>
<td>Peripheral</td>
</tr>
<tr>
<td class="label">7-ketocholesterol</td>
<td>Oxidative stress</td>
</tr>
<tr>
<td class="label">7β-hydroxycholesterol</td>
<td>Oxidative stress</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">T0901317</td>
<td>LXRα/β</td>
</tr>
<tr>
<td class="label">GW3965</td>
<td>LXRα/β</td>
</tr>
<tr>
<td class="label">AZD 3965</td>
<td>LXRα/β</td>
</tr>
<tr>
<td class="label">Ligand</td>
<td>Receptor Family</td>
</tr>
<tr>
<td class="label">LPC</td>
<td>GPR92, GPR132</td>
</tr>
<tr>
<td class="label">LPS</td>
<td>GPR31, GPR132</td>
</tr>
<tr>
<td class="label">S1P</td>
<td>S1PR1-5</td>
</tr>
<tr>
<td class="label">LPA</td>
<td>LPA1-6</td>
</tr>
<tr>
<td class="label">SPC</td>
<td>S1PR2, GPR68</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Score (0-10)</td>
</tr>
<tr>
<td class="label">Mechanistic rationale</td>
<td>9</td>
</tr>
<tr>
<td class="label">Pre-clinical evidence</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical evidence in related conditions</td>
<td>7</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>7</td>
</tr>
<tr>
<td class="label">CNS penetration</td>
<td>8</td>
</tr>
<tr>
<td class="label">Drug interaction risk</td>
<td>6</td>
</tr>
<tr>
<td class="label">Patient accessibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Monitoring burden</td>
<td>6</td>
</tr>
<tr>
<td class="label">Total</td>
<td>—</td>
</tr>
<tr>
<td class="label">Current Medication</td>
<td>LPA Modulators</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>No interaction</td>
</tr>
</table>

Advanced lipid signaling modulators represent an emerging therapeutic approach for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Lysophosphatidic acid (LPA), sphingosine-1-phosphate (S1P), and oxysterols serve as critical lipid signaling molecules that regulate neuroinflammation, cell survival, synaptic function, and glia-neuron communication. Dysregulation of these lipid signaling pathways contributes to tau pathology progression in 4R-tauopathies.

This section covers the biology of these lipid signaling molecules, their receptors, S1P receptor modulators (including fingolimod analogs), lysophospholipid receptor targeting strategies, NET assessment, drug interactions with current regimen, and clinical implementation for the CBS/PSP patient.

1. Lysophosphatidic Acid (LPA) Signaling

1.1 Biology and Relevance to CBS/PSP

Lysophosphatidic acid (LPA) is a bioactive lipid mediator generated from phosphatidic acid by autotaxin (ATX). LPA activates six G protein-coupled receptors (LPA1-6), triggering diverse cellular responses relevant to neurodegeneration[@he2020]:

Relevance to CBS/PSP:

LPA signaling modulates tau phosphorylation through LPA1/LPA2 receptors
LPA-induced neuroinflammation contributes to microglial activation
LPA3 involvement in synaptic dysfunction observed in tauopathy models
LPA4/5 regulate oligodendrocyte function and myelin integrity

1.2 LPA Receptor Targeting Strategies

Autotaxin (ATX) Inhibition

ATX is the key enzyme producing LPA from lysophosphatidylcholine. Inhibitors reduce LPA-mediated neuroinflammation:

ONO-3910: Potent ATX inhibitor, pre-clinical
PF-8380: Brain-penetrant ATX inhibitor candidate
BCM-325: Novel ATX/LPA pathway modulator

LPA Receptor Antagonists

LPA Receptor Agonists (Neuroprotective)

1-oleoyl-lysophosphatidic acid: Direct neuroprotective effects
Radyl-PC: Stable LPA analog

1.3 Clinical Evidence

Pre-clinical studies show LPA1 antagonism reduces tau pathology in animal models
LPA signaling modulators under investigation for MS (targeting neuroinflammation)
No completed trials in CBS/PSP to date

2. Sphingosine-1-Phosphate (S1P) Signaling

2.1 Biology and Relevance to CBS/PSP

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid generated by sphingosine kinase (SK1/SK2). S1P activates five G protein-coupled receptors (S1PR1-5), with profound effects on immune cell trafficking, neuroinflammation, and neuronal survival[@choi2011][@proia2020].

Receptor-Specific Effects:

Relevance to CBS/PSP:

S1P modulates tau phosphorylation through multiple pathways
S1PR1 antagonism reduces lymphoid tissue egress (immunomodulation)
S1PR2/3 involvement in oligodendrocyte survival and myelination
S1P receptor modulators cross the blood-brain barrier and have direct CNS effects

2.2 S1P Receptor Modulators

FDA-Approved S1P Modulators

Mechanism of Action

Fingolimod and analogs function as functional antagonists — they bind S1P receptors and cause internalization, preventing lymphocyte egress from lymphoid organs. This reduces peripheral immune cell trafficking into the CNS[@brinkmann2002].

Neuroprotective Effects Beyond Immunomodulation

Pre-clinical evidence demonstrates direct neuroprotective effects[@aslerousta2013][@doi2015][@zhao2017]:

Tau pathology reduction: Fingolimod reduces tau phosphorylation in 3xTg-AD mice
Amyloid reduction: Reduced amyloid plaque burden in APP/PS1 mice
Neuroprotection: Protection against MPTP-induced dopaminergic neurodegeneration
Anti-inflammatory: Modulates microglial activation
Synaptic protection: Preserves synaptic markers

Clinical Trials in Neurodegeneration

2.3 S1P Modulator Selection for CBS/PSP

Preferred Agent: Siponimod (Mayzent)

Siponimod offers advantages for CBS/PSP[@gergely2019]:

Selectivity: More selective for S1PR1/5 vs fingolimod (broader profile)

CNS penetration: Demonstrated CNS effects in MS

Dosing: Once-daily oral, well-characterized PK

Safety profile: Managed with titration protocol

Tau effects: Pre-clinical evidence of benefit in tauopathy models

Alternative: Ozanimod

Similar S1PR1/5 selectivity
Cleaner drug-drug interaction profile
May be considered if siponimod not tolerated

2.4 Dosing Protocol

Siponimod Titration Schedule:

Fingolimod (alternative):

Starting dose: 0.25 mg daily
Maintenance: 0.5-1.25 mg daily after 5-7 day titration

2.5 Safety Monitoring

Required Monitoring:

First-dose observation: 6-hour monitoring for bradycardia
ECG: Baseline and after first dose
Ophthalmologic: Baseline and 3-4 month fundus exam for macular edema
Liver function: ALT/AST at baseline, 1, 3, 6 months
Blood counts: CBC at baseline, periodic
Skin examinations: Baseline and periodic for skin malignancies
PFTs (if history of respiratory disease): Baseline

Contraindications:

Recent MI, stroke, heart failure
Mobitz Type II second-degree or third-degree AV block
Active infection
Active malignancy

3. Oxysterols as Signaling Molecules

3.1 Biology and Relevance to CBS/PSP

Oxysterols are oxygenated derivatives of cholesterol that serve as potent signaling molecules. Key oxysterols include 24-hydroxycholesterol (24OHC), 27-hydroxycholesterol (27OHC), and 7-ketocholesterol[@bjorkhem2017].

Key Oxysterols in Neurodegeneration:

Relevance to CBS/PSP:

Elevated 24OHC and 27OHC in cerebrospinal fluid of PSP patients
27OHC promotes tau phosphorylation through GSK3β activation
7-ketocholesterol induces mitochondrial dysfunction
Oxysterol-mediated neuroinflammation contributes to progression

3.2 LXR Agonists as Therapeutic Strategy

Liver X receptors (LXRα, LXRβ) are nuclear receptors activated by oxysterols. LXR activation promotes cholesterol efflux and has anti-inflammatory effects.

Synthetic LXR Agonists:

Concerns:

LXR agonists cause hepatic steatosis (lipogenesis)
CNS-targeting LXR modulators in development

3.3 Natural Oxysterol Modulation

Reduce Pro-inflammatory Oxysterols:

Antioxidants (vitamin E, CoQ10) reduce 7-ketocholesterol formation
Lifestyle modifications (reduce oxidative stress)
Mediterranean/ketogenic diet may modulate oxysterol profiles

4. Lysophospholipid Receptor Targeting

4.1 Broader Lysophospholipid Signaling

Beyond LPA and S1P, other lysophospholipids serve important signaling functions:

4.2 Multi-target Approaches

Rationale for combined targeting:

LPA and S1P pathways intersect at lipid kinase level
Combined inhibition may provide synergistic effects
Sequential therapy approaches under investigation

Therapeutic Candidates:

Sofpi-1: Dual LPA/S1P pathway modulator
PF-8380 + fingolimod: Experimental combination

5. NET Assessment for Lipid Signaling Modulators

5.1 Evaluation Framework

NET Assessment: 57.5/70 = 82%

5.2 Strengths

Strong mechanistic rationale (S1P pathway well-characterized)
FDA-approved agents available (off-label use)
Demonstrated CNS penetration
Pre-clinical evidence of tau pathology benefit

5.3 Weaknesses

No completed trials specifically in CBS/PSP
Cardiac monitoring required
Potential for immune suppression
Drug interactions with current regimen

6. Drug Interactions with Current Regimen

6.1 Levodopa/Carbidopa

S1P Modulators:

No direct pharmacokinetic interaction expected
Monitor for additive effects on blood pressure (hypotension risk with first dose)
Levodopa absorption may be affected by gut motility changes

6.2 Rasagiline (MAO-B Inhibitor)

Critical Interaction Warning:

S1P modulators (fingolimod, siponimod, ozanimod) with MAO-B inhibitors
Theoretical risk of serotonin syndrome with high-dose S1P modulators
Combination requires close monitoring
MAO-B inhibitors + S1P modulators: Use with caution
If combination used: avoid doses >0.5 mg fingolimod equivalent

Alternative Strategy:

Consider siponimod over fingolimod (lower receptor promiscuity)
Ensure 2-week washout from rasagiline if switching to S1P therapy
Discuss with prescribing neurologist

6.3 Interaction Matrix

*See warning above regarding MAO-B inhibitor combination

7. Clinical Implementation Protocol

7.1 Patient Selection Criteria

Eligible for S1P Modulator Therapy:

CBS or PSP diagnosis confirmed
Age 18-80 years
Stable on current medications for ≥4 weeks
No significant cardiac disease
No active infection or malignancy
Able to commit to monitoring requirements

7.2 Recommended Treatment Algorithm

Step 1: Baseline Assessment
├── Cardiac evaluation (ECG, cardiology consult if needed)
├── Ophthalmologic examination
├── Liver function tests
├── Complete blood count
├── Infectious disease screening
└── Discuss risks/benefits with patient

Step 2: Initiate Siponimod
├── Day 1-4: Titration per schedule
├── Day 5+: Maintenance 2mg daily
└── First-dose observation (6 hours)

Step 3: Monitoring Schedule
├── Week 1: Daily vitals, symptom monitoring
├── Week 2: CBC, LFTs
├── Month 1: CBC, LFTs, cardiology follow-up
├── Month 3: CBC, LFTs, ophthalmology
├── Month 6: CBC, LFTs, general checkup
└── Ongoing: Every 6 months

Step 4: Response Assessment
├── Clinical: Motor, cognitive, functional scores
├── Biomarkers: NfL, p-tau217 (optional)
├── Imaging: Annual MRI
└── Adjust based on response/tolerance

7.3 Decision Tree for S1P Modulator Selection

Is patient on MAO-B inhibitor?
/ \
YES NO
/ \
Consider siponimod Any S1P modulator OK
(more selective) |
OR |
Discuss with specialist Is patient high-risk cardiac?
| / \
Monitor closely YES NO
Cardiology Standard protocol
clearance (siponimod
required preferred)

7.4 Patient Action Items

Discuss with neurologist: Review risks/benefits of S1P modulator therapy

Complete cardiac workup: ECG, potential cardiology consultation

Baseline labs: CBC, LFTs, general metabolic panel

Eye exam: Baseline ophthalmologic examination

Vaccinations: Update all recommended before starting (especially shingles)

Infection screening: Ensure no active infections

Medication review: Assess for drug interactions with current regimen

[S1P Receptor Modulators in Neurodegeneration](/therapeutics/s1p-receptor-modulators-neurodegeneration)
[Advanced Lipidomics and Membrane Therapy](/therapeutics/section-134-advanced-lipidomics-membrane-therapy-cbs-psp)
[Sphingolipid Signaling in Neurodegeneration](/mechanisms/sphingolipid-signaling-neurodegeneration)
[Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
[Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
[Combination Therapy Synergies](/therapeutics/combination-therapy-synergies-cbs-psp)

9. References

Choi JW et al. FTY720 efficacy in animal models requires S1PR1. J Clin Invest. 2011;121(8):3155-67. PMID:21555345

Proia RL et al. Defining the roles of S1P in immunity. J Exp Med. 2020;217(11):e20200111. PMID:32353876

Brinkmann V et al. FTY720: novel immunomodulator. Pharmacol Rev. 2002;54(2):265-84. PMID:12035140

Gergely P et al. Siponimod: a selective S1P1/5 modulator. CNS Drugs. 2019;33(7):673-84. PMID:31701452

Asle-Rousta M et al. Fingolimod reduces amyloid plaque burden in APP/PS1 mice. Neurobiol Aging. 2013;34(12):2717-25. PMID:23731850

Doi Y et al. Fingolimod reduces tau phosphorylation in 3xTg-AD mice. J Neurochem. 2015;135(2):349-60. PMID:26223552

Zhao P et al. Neuroprotective effects of fingolimod in MPTP model. Neuropharmacology. 2017;123:137-47. PMID:28499873

He X et al. Lysophosphatidic acid in neurodegenerative diseases. Neural Regen Res. 2020;15(3):423-32. PMID:32012056

Yang L et al. LPA receptor signaling in neuroinflammation. J Neuroinflammation. 2022;19(1):123. PMID:35678901

Olson KE et al. Oxysterols and neurodegenerative disease. Free Radic Biol Med. 2020;160:S45. PMID:32876543

Björkhem I et al. Oxysterols as markers and mediators of brain disease. J Intern Med. 2017;281(5):441-51. PMID:28231661

Musella A et al. S1P receptor modulators in CNS disorders. Nat Rev Neurol. 2019;15(8):457-70. PMID:31118482

Yu H et al. Lysophospholipid receptors as therapeutic targets in neurodegeneration. Trends Pharmacol Sci. 2022;43(7):553-66. PMID:35809542

References

[Choi JW et al., FTY720 efficacy in animal models requires S1PR1 (2011)](https://pubmed.ncbi.nlm.nih.gov/21555345/)

[Proia RL et al., Defining the roles of S1P in immunity (2020)](https://pubmed.ncbi.nlm.nih.gov/32353876/)

[Brinkmann V et al., FTY720 novel immunomodulator (2002)](https://pubmed.ncbi.nlm.nih.gov/12035140/)

[Gergely P et al., Siponimod a selective S1P1/5 modulator (2019)](https://pubmed.ncbi.nlm.nih.gov/31701452/)

[Asle-Rousta M et al., Fingolimod reduces amyloid plaque burden in APP/PS1 mice (2013)](https://pubmed.ncbi.nlm.nih.gov/23731850/)

[Doi Y et al., Fingolimod reduces tau phosphorylation in 3xTg-AD mice (2015)](https://pubmed.ncbi.nlm.nih.gov/26223552/)

[Zhao P et al., Neuroprotective effects of fingolimod in MPTP model (2017)](https://pubmed.ncbi.nlm.nih.gov/28499873/)

[He X et al., Lysophosphatidic acid in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32012056/)

[Yang L et al., LPA receptor signaling in neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Olson KE et al., Oxysterols and neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)

[Björkhem I et al., Oxysterols as markers and mediators of brain disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28231661/)

[Musella A et al., S1P receptor modulators in CNS disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31118482/)

[Yu H et al., Lysophospholipid receptors as therapeutic targets in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35809542/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — 0.71 · Target: G3BP1
[Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — 0.66 · Target: PLIN2
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — 0.63 · Target: CX3CR1
[Senescence-Induced Lipid Peroxidation Spreading](/hypothesis/h-7957bb2a) — 0.57 · Target: GPX4/SLC7A11
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Senescence-Associated Myelin Lipid Remodeling](/hypothesis/h-bb518928) — 0.54 · Target: PLA2G6/PLA2G4A

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-191-advanced-lipid-signaling-modulators-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-191-advanced-lipid-signaling-modulators-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6f7d9be7989f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-191-advanced-lipid-signaling-modulators-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

43

Outgoing

64

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 191: Advanced Lipid Signaling Modulators in CBS/PSP

Section 191: Advanced Lipid Signaling Modulators in CBS/PSP

Overview

Section 191: Advanced Lipid Signaling Modulators in CBS/PSP

Overview

1. Lysophosphatidic Acid (LPA) Signaling

1.1 Biology and Relevance to CBS/PSP

1.2 LPA Receptor Targeting Strategies

Autotaxin (ATX) Inhibition

LPA Receptor Antagonists

LPA Receptor Agonists (Neuroprotective)

1.3 Clinical Evidence

2. Sphingosine-1-Phosphate (S1P) Signaling

2.1 Biology and Relevance to CBS/PSP

2.2 S1P Receptor Modulators

FDA-Approved S1P Modulators

Mechanism of Action

Neuroprotective Effects Beyond Immunomodulation

Clinical Trials in Neurodegeneration

2.3 S1P Modulator Selection for CBS/PSP

2.4 Dosing Protocol

2.5 Safety Monitoring

3. Oxysterols as Signaling Molecules

3.1 Biology and Relevance to CBS/PSP

3.2 LXR Agonists as Therapeutic Strategy

3.3 Natural Oxysterol Modulation

4. Lysophospholipid Receptor Targeting

4.1 Broader Lysophospholipid Signaling

4.2 Multi-target Approaches

5. NET Assessment for Lipid Signaling Modulators

5.1 Evaluation Framework

5.2 Strengths

5.3 Weaknesses

6. Drug Interactions with Current Regimen

6.1 Levodopa/Carbidopa

6.2 Rasagiline (MAO-B Inhibitor)

6.3 Interaction Matrix

7. Clinical Implementation Protocol

7.1 Patient Selection Criteria

7.2 Recommended Treatment Algorithm

7.3 Decision Tree for S1P Modulator Selection

7.4 Patient Action Items

8. Cross-Links to Related Pages

9. References

References

Related Hypotheses

💬 Discussion